These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP. J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371 [Abstract] [Full Text] [Related]
28. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Kobelt G, Lindgren P, Singh A, Klareskog L. Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879 [Abstract] [Full Text] [Related]
29. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saisho K, Shimada K, Tohma S. Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281 [Abstract] [Full Text] [Related]
31. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study. Kim SK, Choe JY, Park SH, Lee H. Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795 [Abstract] [Full Text] [Related]
32. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs? Ciubotariu E, Gabay C, Finckh A, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383 [Abstract] [Full Text] [Related]
33. Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis. Jurgens MS, Overman CL, Jacobs JW, Geenen R, Cuppen BV, Marijnissen AC, Bijlsma JW, Welsing PM, Lafeber FP, van Laar JM, Utrecht Arthritis Cohort Study Group. Arthritis Care Res (Hoboken); 2015 Jul; 67(7):923-8. PubMed ID: 25504811 [Abstract] [Full Text] [Related]
37. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Chatzidionysiou K, Kristensen LE, Eriksson J, Askling J, van Vollenhoven R, ARTIS Group. Scand J Rheumatol; 2015 Jul; 44(6):431-7. PubMed ID: 26084325 [Abstract] [Full Text] [Related]
39. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daurès JP, Dougados M. Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234 [Abstract] [Full Text] [Related]